Oncology coverage across community and academic centers.
Targeted therapies, immunotherapies, supportive care, and biomarker diagnostics.
Oncology dynamics.
Oncology is the most demanding therapeutic sales environment in medicine. Decisions are multidisciplinary (medical oncologist + surgical oncologist + radiation oncologist + pathologist), evidence-driven, and economically complex (350B Drug Pricing, buy-and-bill, Medicare Part B vs D). The category spans community oncology (US Oncology, OneOncology, Florida Cancer Specialists) and academic medical centers, each with distinct buying motions.
Why this specialty fits Solara reps.
Solara oncology reps carry portfolios that respect the multidisciplinary buying motion — targeted therapies alongside biomarker diagnostics and supportive care. Per-physician influence is high; per-prescription economics are durable.
Apply to the networkWhat Solara delivers for oncology launches.
Manufacturers launching into oncology need coverage at the community oncology platforms (US Oncology Network, OneOncology, FCS, Texas Oncology) and at the academic medical centers. Solara's network covers both, with adoption telemetry at the platform, practice, and physician level.
Book a working sessionWhat Oncology reps see most.
- ·Breast cancer (HR+/HER2+/triple-negative)
- ·Non-small cell lung cancer
- ·Colorectal cancer
- ·Prostate cancer (advanced)
- ·Hematologic malignancies (CLL, MM, AML)
- ·Melanoma
- ·Ovarian cancer
Procedures that anchor the buying motion.
- 96413Chemotherapy infusion, IV, first hour
- 96415Chemotherapy infusion, IV, additional hour
- 96367Therapeutic prophylactic IV infusion
- 38221Bone marrow biopsy
- 88305Pathology, surgical specimens, level 4
Product categories most relevant to oncology.
Common questions about oncology on Solara.
- Does Solara cover the large community oncology platforms?
Yes. US Oncology Network, OneOncology, Florida Cancer Specialists, Texas Oncology, and the regional community-oncology platforms are part of the network coverage. Reps maintain relationships at platform pharmacy directors, medical directors, and individual oncologists.
- Can Solara support biomarker-driven targeted therapy launches?
Yes. Targeted therapies with biomarker requirements (EGFR, ALK, BRCA, KRAS G12C, etc.) require coordinated rep activity across the prescribing oncologist, pathology, and diagnostic-testing workflow. Solara reps are trained on the testing landscape and the cross-stakeholder buying motion.
- How does Solara handle the 340B and Medicare Part B/D dynamics?
Oncology economics are dominated by 340B status, Part B vs Part D coverage, and ASP-based reimbursement. Reps are trained on the payer-aware messaging for each site of service and on the patient-support resources manufacturers provide.
- What targeting data is used for oncology?
Disease-state prescribing patterns where reportable, platform/practice affiliation, 340B status, academic-center vs community-practice profile, and biomarker testing intensity. ICP scoring surfaces oncologists with the right disease mix and prescribing profile.
See your oncology territory.
Drop in your metro on the territory preview tool — we'll surface the top 50 physicians most likely to adopt your product, scored on five signals.